Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.8
5.6
Journals
IJMS
Special Issues
Novel Advances on Systemic Lupus Erythematosus and Antiphospholipid Syndrome
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Novel Advances on Systemic Lupus Erythematosus and Antiphospholipid Syndrome

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 August 2024 | Viewed by 5439

Special Issue Editor

Prof. Dr. Tatiana M. Reshetnyak

E-Mail Website
Guest Editor
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia
Interests: systemic lupus erythematosus; antiphospholipid syndrome; IgA antiphospholipid antibodies; neutrophils; thromboembolic complications; spondylitis; immune-mediated inflammatory rheumatic disease

Special Issue Information

Dear Colleagues,

Systemic lupus erythematosus (SLE) is an autoimmune disorder that affects multiple organs and systems in the body. It is characterized by inflammation, pain, and damage to the skin, joints, and other organs. Antiphospholipid syndrome (APS) is a disorder that is associated with SLE, and is characterized by the presence of antiphospholipid antibodies in the blood. These antibodies can cause blood clots, which can lead to stroke, heart attack, and other serious complications.

Antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) are interconnected autoimmune diseases. However, in recent years, a sufficient amount of knowledge has been accumulated indicating that APS is a systemic autoimmune thrombo-inflammatory disease. The pathogenesis of these clinical manifestations in APS is not directly related to the development of thrombosis, and these manifestations can persist, progress over time, or occur during appropriate anticoagulation therapy. In some cases, the prescription of immunosuppressive drugs is required, which indicates the role of inflammation in their development. It is important to study the mechanisms of disease development and find new therapeutic targets. In this Special Issue, we will include original research articles and reviews/metanalyses reporting on innovative aspects related to the pathogenesis and clinical manifestations, as well as principles of therapy of patients with SLE and APS. 

Prof. Dr. Tatiana M. Reshetnyak
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • netosis
  • thromboinflammation
  • thrombosis
  • anticoagulants
  • antiphospholipid syndrome
  • systemic lupus erythematosus

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

22 pages, 1200 KiB  
Editorial
The Role of Neutrophil Extracellular Traps (NETs) in the Pathogenesis of Systemic Lupus Erythematosus and Antiphospholipid Syndrome
by Tatiana Reshetnyak and Kamila Nurbaeva
Int. J. Mol. Sci. 2023, 24(17), 13581; https://doi.org/10.3390/ijms241713581 - 1 Sep 2023
Cited by 3 | Viewed by 2070
Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease of unknown aetiology [...] Full article
(This article belongs to the Special Issue Novel Advances on Systemic Lupus Erythematosus and Antiphospholipid Syndrome)
►▼ Show Figures

Figure 1

Research

Jump to: Editorial

12 pages, 608 KiB  
Article
Association of IL10RA, IL10RB, and IL22RA Polymorphisms/Haplotypes with Susceptibility to and Clinical Manifestations of SLE
by Milka Grk, Rada Miskovic, Ivica Jeremic, Milica Basaric, Marija Dusanovic Pjevic, Biljana Jekic, Danijela Miljanovic, Ivana Lazarevic, Aleksa Despotovic, Andja Cirkovic and Ana Banko
Int. J. Mol. Sci. 2023, 24(14), 11292; https://doi.org/10.3390/ijms241411292 - 10 Jul 2023
Viewed by 1124
Abstract
Systemic lupus erythematosus (SLE) is characterized by an imbalance between proinflammatory and anti-inflammatory mediators. Single-nucleotide polymorphisms (SNPs) in genes coding IL10RA, IL10RB, and IL22RA could affect their expression or function and disrupt immune homeostasis. We aimed to analyze the associations of [...] Read more.
Systemic lupus erythematosus (SLE) is characterized by an imbalance between proinflammatory and anti-inflammatory mediators. Single-nucleotide polymorphisms (SNPs) in genes coding IL10RA, IL10RB, and IL22RA could affect their expression or function and disrupt immune homeostasis. We aimed to analyze the associations of IL10RA, IL10RB, and IL22RA polymorphisms/haplotypes with patients’ susceptibility to and clinical manifestations of SLE. Our study included 103 SLE patients and 99 healthy controls. The genotypes of the selected polymorphisms within IL10RA (rs10892202, rs4252270, rs3135932, rs2228055, rs2229113, and rs9610), IL10RB (rs999788, rs2834167, and rs1058867), and IL22RA (rs3795299 and rs16829204) genes were determined by TaqMan® Assays. IL10RB rs1058867 G allele carriers were significantly more frequent among the controls than among the SLE patients (76.8% vs. 61.2%; p = 0.017, OR = 0.477, 95% CI: 0.258–0.879). The IL10RB CAA haplotype was more frequent among the SLE patients than in the control group (42.7% vs. 30.7%; p = 0.027). The IL22RA rs3795299 C allele and rs16829204 CC genotype were associated with Hashimoto thyroiditis in the SLE patients (n = 103; p = 0.002 and p = 0.026, respectively), and in all the included participants (n = 202, p < 0.000 and p = 0.007, respectively), and the IL22RA CC haplotype was more frequent in the SLE patients with Hashimoto thyroiditis (p = 0.047) and in the overall participants with Hashimoto thyroiditis (n = 32, p = 0.004). The IL10RA, IL10RB, and IL22RA polymorphisms/haplotypes could be associated with SLE susceptibility and various clinical manifestations, and the IL22RA CC haplotype could be associated with Hashimoto thyroiditis. Full article
(This article belongs to the Special Issue Novel Advances on Systemic Lupus Erythematosus and Antiphospholipid Syndrome)
►▼ Show Figures

Figure 1

19 pages, 4278 KiB  
Article
Markers of NETosis in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome
by Tatiana Reshetnyak, Kamila Nurbaeva, Ivan Ptashnik, Anna Kudriaeva, Alexey Belogurov, Jr., Aleksandr Lila and Evgeny Nasonov
Int. J. Mol. Sci. 2023, 24(11), 9210; https://doi.org/10.3390/ijms24119210 - 24 May 2023
Cited by 8 | Viewed by 1831
Abstract
Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase–deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for [...] Read more.
Neutrophil Extracellular Traps (NETs) have been implicated in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) pathogenesis. The myeloperoxidase–deoxyribonucleic acid (MPO-DNA) complex and nucleosomes are serum markers of NETosis. The aim of this study was to assess these NETosis parameters as markers for SLE and APS diagnosis and their association with clinical features and disease activity. A total of 138 people were included in the cross-sectional study: 30 with SLE without APS, 47 with SLE and APS, 41 patients with primary antiphospholipid syndrome (PAPS), and 20 seemingly healthy individuals. Serum MPO-DNA complex and nucleosome levels were determined via an enzyme-linked immunosorbent assay (ELISA). Informed consent was obtained from all subjects involved in the study. The Ethics Committee of the V.A. Nasonova Research Institute of Rheumatology (Protocol No. 25 dated 23 December 2021) approved the study. In patients with SLE without APS, the levels of the MPO-DNA complex were significantly higher compared to patients with SLE with APS, with PAPS, and healthy controls (p < 0.0001). Among patients with a reliable diagnosis of SLE, 30 had positive values of the MPO-DNA complex, of whom 18 had SLE without APS, and 12 had SLE with APS. Patients with SLE and positive MPO-DNA complex levels were significantly more likely to have high SLE activity (χ2 = 5.25, p = 0.037), lupus glomerulonephritis (χ2 = 6.82, p = 0.009), positive antibodies to dsDNA (χ2 = 4.82, p = 0.036), and hypocomplementemia (χ2 = 6.72, p = 0.01). Elevated MPO-DNA levels were observed in 22 patients with APS: 12 with SLE with APS and 10 with PAPS. There were no significant associations between positive levels of the MPO-DNA complex and clinical and laboratory manifestations of APS. The concentration of nucleosomes was significantly lower in the group of SLE patients (±APS) compared to controls and PAPS (p < 0.0001). In SLE patients, the frequency of low nucleosome levels was associated with high SLE activity (χ2 = 13.4, p < 0.0001), lupus nephritis (χ2 = 4.1, p = 0.043), and arthritis (χ2 = 3.89, p = 0.048). An increase in the specific marker of NETosis, the MPO-DNA complex, was found in the blood serum of SLE patients without APS. Elevated levels of the MPO-DNA complex can be regarded as a promising biomarker of lupus nephritis, disease activity, and immunological disorders in SLE patients. Lower levels of nucleosomes were significantly associated with SLE (±APS). Low nucleosome levels were more common in patients with high SLE activity, lupus nephritis, and arthritis. Full article
(This article belongs to the Special Issue Novel Advances on Systemic Lupus Erythematosus and Antiphospholipid Syndrome)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop